[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 27, 1997

Atheroembolism or Cholesterol Crystal Embolization

Author Affiliations

Wellington, New Zealand

Arch Intern Med. 1997;157(2):244-245. doi:10.1001/archinte.1997.00440230124021

The recent article by Moolenaar and Lamers1 on cholesterol crystal embolization in the Netherlands, which was based on national pathologic data, is of interest, but the conclusions that were reached could impart a false impression of the frequency distribution of this phenomenon in the body. The authors assert that the primary site of what is usually referred to as atheroembolism is the kidney, followed by the skin and gastrointestinal tract. Atheroembolism in the kidney is more likely to result in clinical recognition because of the kidney's relatively high blood flow, functional importance, paucity of collateral flow, and the potential for secondary hypertension when the kidney is ischemic.

The study primarily concerns clinically manifest disease rather than the prevalence of atheroembolism per se, given that 67.2% of the pathology reports were based on antemortem reports of biopsies or resections and the remainder on autopsies with the potential for providing more

First Page Preview View Large
First page PDF preview
First page PDF preview